GBS - GBS STOCK NEWS

GBS Inc. will release its financial results for the third quarter ended March 31, 2022, on May 10, after the NASDAQ market close. A conference call and webcast will be held at 4:30 p.m. ET to discuss these results. GBS specializes in developing non-invasive, real-time diagnostic tests, particularly for diabetes management using its innovative Biosensor Platform. Investors can access the live webcast through the company's website, with a replay available afterwards.

GBS Inc. has received IRB approval to begin enrolling approximately 40 adults with type 2 diabetes for a clinical study aimed at validating its next-generation Saliva Glucose Biosensor. This single-center, prospective study will take place at Sutter Health’s Mills-Peninsula Medical Center. Initial data collection is slated for 2Q’22, with results expected for publication in 2H’22. GBS aims to correlate glucose levels in saliva and blood samples to improve diabetes management and non-invasive testing capabilities.

GBS (Nasdaq: GBS) has announced participation in two key conferences in March 2022. The 34th Annual Roth Conference will be held from March 13-15 in Dana Point, CA, featuring a fireside chat on March 15 at 11:00 AM. The Maxim Virtual Growth Conference is scheduled for March 28-30, running from 9:00 AM to 5:30 PM ET. Investors can access webcasts on GBS's website, with replays available for 90 days. Interested parties can arrange one-on-one meetings through conference representatives.

GBS Inc. announced its financial results for Q2 2022, reporting approximately $11.19 million in cash and equivalents, providing a runway into H1 2023. The company is focused on developing a saliva-based glucose testing platform and is in discussions with the University of Newcastle to establish a high-tech manufacturing facility, aided by a $4.7 million government grant. Key clinical trials are underway, with a preliminary net loss of $3.46 million or $0.23 per share, primarily due to increased development costs.

GBS Inc. will release its financial results for the second quarter ending December 31, 2021, after NASDAQ market close on February 10, 2022. A conference call is scheduled for 4:30 p.m. ET on the same day, where management will discuss the results. Interested parties can join the call via toll-free numbers or through a webcast available on the company’s website. GBS is focused on developing non-invasive diagnostic tests for diabetes management.

GBS (Nasdaq: GBS), a life sciences firm focusing on non-invasive diagnostic testing, has announced the participation of interim CEO Dr. Steven Boyages and the management team in upcoming January conferences. The events include the 11th Annual LifeSci Partners Corporate Access Event from January 5-7 and the H.C. Wainwright BioConnect Virtual Conference from January 10-12. Investors are invited to register for one-on-one meetings. GBS is developing a world-first Biosensor Platform aimed at enhancing diabetes management.

GBS Inc. (Nasdaq: GBS) announced a collaboration with Life Science Biosensor Diagnostics Pty Ltd (LSBD) to seek FDA Breakthrough Device Designation for a non-invasive Saliva Glucose Test. This initiative aims to expedite the regulatory approval process, targeting improved diabetes management. GBS holds licenses for the Biosensor Platform across the APAC and North American regions, which includes multiple diagnostic tests. The technology is expected to help millions with diabetes, especially amid rising morbidity linked to poor diabetes control during the COVID-19 pandemic.

GBS Inc. (Nasdaq: GBS) announced plans to prepare for clinical trials of its rapid SARS-CoV-2 Antibody test after successfully completing a clinical validation study. Conducted at Harvard's Wyss Institute, the study reported the biosensor assay's sensitivity and specificity at 100%. Results can be obtained in under 10 minutes. GBS is now looking to initiate saliva-based trials, aiming to submit an Emergency Use Authorization request to the FDA. Interim CEO Dr. Steven Boyages emphasized the critical need for such tests in the ongoing battle against COVID-19 variants.

GBS Inc. announced key developments including a pre-submission package to the FDA for its glucose biosensor and positive clinical results for its SARS-CoV-2 antibody test, showcasing 100% sensitivity and specificity. The company secured a $4.7 million grant from the Australian government for manufacturing expansion and holds $12.6 million in cash and equivalents, ensuring a runway into H1 2023. Despite a net loss of $1.4 million for Q1 2022, GBS aims to finalize clinical trial protocols and explore commercial partnerships in the APAC region.